F
FLOW Trial
Study / ResearchMentioned in 1 video
A chronic kidney disease trial that had to be halted in late 2023 because the GLP-1 substance was so effective at reversing kidney damage, making it unethical to withhold from the control group.
A chronic kidney disease trial that had to be halted in late 2023 because the GLP-1 substance was so effective at reversing kidney damage, making it unethical to withhold from the control group.